HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer

被引：28

作者：

Inui, T.

Asakawa, A.

Morita, Y.

Mizuno, S.

Natori, T.

Kawaguchi, A.

Murakami, M.

Hishikawa, Y.

Inui, A.

机构：

[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Behav Med, Kagoshima 8908520, Japan

[2] Kagoshima Univ, Grad Sch Med & Dent Sci, Inui Clin, Kagoshima 8908520, Japan

[3] Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis, Kobe, Hyogo 657, Japan

[4] Kinki Univ, Sch Med, Dept Gastroenterol, Osaka 577, Japan

[5] SRL Lab, Tokyo, Japan

[6] Kobe Univ, Grad Sch Med, Dept Radiol, Hyogo Ion Beam Med Ctr, Kobe, Hyogo 657, Japan

[7] Kobe Univ, Grad Sch Med, Div Med Imaging & Ion Beam Therapy, Kobe, Hyogo 657, Japan

来源：

JOURNAL OF INTERNAL MEDICINE | 2006年 / 260卷 / 05期

关键词：

gastric cancer; HER-2; overexpression; personalized therapy; proton ion beam; trastuzumab;

D O I：

10.1111/j.1365-2796.2006.01715.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inui T, Asakawa A, Morita Y, Mizuno S, Natori T, Kawaguchi A, Murakami M, Hishikawa Y, Inui A (Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima; and Kinki University School of Medicine, Osaka, Japan). HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer (Case report).

引用

收藏

页码：484 / 487

页数：4

相关论文

共 14 条

[1] Epidermal growth factor receptor blockade: An emerging therapeutic modality in gastroenterology [J].

Barnard, J .

GASTROENTEROLOGY, 2001, 120 (07) :1872-1874

[2] Targeted therapy in cancer and transgenic animal model [J].

Inui, A .

CANCER INVESTIGATION, 2003, 21 (05) :819-820

[3] Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].

Joensuu, H ;

Roberts, PJ ;

Sarlomo-Rikala, M ;

Andersson, LC ;

Tervahartiala, P ;

Tuveson, D ;

Silberman, SL ;

Capdeville, R ;

Dimitrijevic, S ;

Druker, B ;

Demetri, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056

[4] Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center [J].

Kagawa, K ;

Murakami, M ;

Hishikawa, Y ;

Abe, M ;

Akagi, T ;

Yanou, T ;

Kagiya, G ;

Furusawa, Y ;

Ando, K ;

Nojima, K ;

Aoki, M ;

Kanai, T .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (03) :928-938

[5] New targeted therapies in breast cancer [J].

Kaklamani, V ;

O'Regan, RM .

SEMINARS IN ONCOLOGY, 2004, 31 (02) :20-25

[6] The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer [J].

Kapitanovic, S ;

Radosevic, S ;

Kapitanovic, M ;

Andelinovic, S ;

Ferencic, Z ;

Tavassoli, M ;

Primorac, D ;

Sonicki, Z ;

Spaventi, S ;

Pavelic, K ;

Spaventi, R .

GASTROENTEROLOGY, 1997, 112 (04) :1103-1113

[7] Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth [J].

Mann, M ;

Sheng, HM ;

Shao, JY ;

Williams, CS ;

Pisacane, PI ;

Sliwkowski, MX ;

DuBois, RN .

GASTROENTEROLOGY, 2001, 120 (07) :1713-1719

[8] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[9] The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein [J].

Rebischung C. ;

Barnoud R. ;

Stéfani L. ;

Faucheron J.-L. ;

Mousseau M. .

Gastric Cancer, 2005, 8 (4) :249-252

[10] The HER-2/neu oncogene in tumors of the gastrointestinal tract [J].

Ross, JS ;

McKenna, BJ .

CANCER INVESTIGATION, 2001, 19 (05) :554-568